Brief: Cantargia Presents New Preclinical Data On Nadunolimab
20/09/2023 11:04
Sept 20 (Reuters) - Cantargia AB CANTA.ST :
* NEW PRECLINICAL DATA ON NADUNOLIMAB POTENTIAL TO ENHANCE
ANTI-TUMOR EFFECT OF IMMUNOTHERAPY PRESENTED AT CRI-ENCI-AACR
* DATA SHOW THAT NADUNOLIMAB REDUCES IMMUNE SUPPRESSION AND
IMPROVES ANTI-TUMOR EFFECT OF A CANCER VACCINE
Source text for Eikon: ID:nMFN24N5JZ
Further company coverage: CANTA.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))